Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SD-101 + ribavirin
- Development stage
- Phase 1
- Lead developer
- Dynavax Technologies
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules
- Administration
- Subcutaneous, Oral
01
Overview
SD-101 + ribavirin is an experimental combination therapy consisting of SD-101, a synthetic CpG oligonucleotide and Toll-like receptor 9 (TLR9) agonist, and ribavirin, a broad-spectrum antiviral small molecule. SD-101 is designed to stimulate innate immune responses through TLR9 activation, promoting antiviral and immunomodulatory effects. Ribavirin inhibits viral RNA synthesis and viral mRNA capping through multiple mechanisms. This combination was explored for its potential to enhance antiviral efficacy in chronic hepatitis C by combining direct antiviral effects (ribavirin) with immune system priming (SD-101)[6][8].
02
Targets
IMPDH (Inosine-5'-monophosphate dehydrogenase 1)TLR9 (Toll-like receptor 9)RdRp (Coronavirus RNA-dependent RNA polymerase)
Beyond the preview
Go deeper on SD-101 + ribavirin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SD-101 + ribavirin.